Retevmo es el nombre de la terapia que será utilizada para el cáncer metastásico como casos de cáncer de tiroides, sobre todo en adultos mayores que padecen esta anomalía.
Retevmo is a selective RET kinase inhibitor. Retevmo may affect both tumor cells and healthy cells, which can result in side effects. Retevmo is an oral prescription medicine, 120 mg or 160 mg based on weight, taken twice daily until disease progression or unacceptable toxicity
